Competitor Analysis: Immunotherapy of Alzheimer's Disease -





The Competitive Intelligence Report Immunotherapy of Alzheimer’s Disease as of May 2012 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease including those targeting amyloid-beta (beta-amyloid) and tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.  

The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of immunotherapeutics for Alzheimer’s disease. Competitor projects are listed in a tabular format providing Information on: 

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product category/Therapeutic Area,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
 

About Competitor Analysis Series: 

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.  

 

 

 

Index 

1) Passive Immunotherapy 

Antibodies against amyloid
Antibodies against tau
Antibodies against other targets
Intravenous Immunoglobulin (IVIG)
2) Active Immunotherapy
 

Vaccines against amyloid
Vaccines against tau
3 ) Corporate AD Immunotherapy R&D Pipelines
 

4) About La Merie